CVS Health Corporation — CVS
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $74.99 | $96.11B | 53.9 | 9.2 | 22.6% | 3.4% | $2.66 3.5% | 1.3 |
Latest Headlines
- · Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
- · How Investors Are Reacting To CVS Health (CVS) Insulin Case Settlement Talks And Shareholder Rights Clash
- · CVS Health Faces FTC Insulin Deal And Proxy Access Governance Test
- · Baum Family Investments Announces Strong Q1 2026 Investment Activity and Expanding Pipeline
- · CVS Health Just Got a $13 Billion Reprieve. Here's Why the Stock Could Keep Climbing.
- · CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors
Revenue & Net Income
| Date | Revenue | Net_Income | EPS | Last_Updated | Revenue_Change | Net_Income_Change | EPS_Change | |
|---|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $268,706M | $7,179M | $5.48 | 2024-02-03 03:17:10 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $322,467M | $4,311M | $6.00 | 2026-03-11 08:32:35 | 20.0% | -39.9% | 9.5% |
| 2 | 2022-12-31 | $322,467M | $4,311M | $3.29 | 2026-04-15 21:52:16 | 0.0% | 0.0% | -45.2% |
| 3 | 2023-12-31 | $357,776M | $8,344M | $6.49 | 2026-04-15 21:52:16 | 10.9% | 93.6% | 97.3% |
| 4 | 2024-12-31 | $372,809M | $4,614M | $3.67 | 2026-04-15 21:52:16 | 4.2% | -44.7% | -43.5% |
| 5 | 2025-12-31 | $402,067M | $1,768M | $1.40 | 2026-04-15 21:52:16 | 7.8% | -61.7% | -61.9% |
| 6 | TTM 2025-12-31 | $402,067M | $1,768M | $1.39 | 2026-02-12 08:37:43 | 0.0% | 0.0% | -0.7% |
EPS
Forecasts
Y/Y % Change
CVS Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | Average | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 20.0% | 0.0% | 10.9% | 4.2% | 7.8% | 1.0% | 4.4% | 6.9% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | |
| EPS Growth (%) | -39.9% | 0.0% | 93.6% | -44.7% | -61.7% | 417.6% | 14.3% | 54.2% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 10 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | Facilities / D&A ($) |
|---|---|---|---|
| 2022 | $322.5B | $263.7B | $4.2B |
| 2023 | $357.8B | $299.0B | $4.4B |
| 2024 | $372.8B | $316.8B | $4.6B |
| 2025 | $402.1B | $342.1B | $4.6B |
| TTM | $402.1B | $342.1B | $4.6B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|
| 2023 | 10.95 | 13.36 | 3.36 |
| 2024 | 4.20 | 5.96 | 5.29 |
| 2025 | 7.85 | 7.98 | 0.20 |
| TTM | 0.00 | 0.00 | 0.00 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $255,327M |
| 1 | Cash | $9,098M |
| 2 | Total Liabilities | $182,217M |
| 3 | Total Debt | $81,752M |
| 4 | Total Equity | $72,928M |
| 5 | Debt to Equity Ratio | 1.12 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $74.99 | 4.3% | Nicks Growth: 5% Nick's Expected Margin: 2% FINVIZ Growth: 12% |
Nicks: 11 Finviz: 21 |
Nick's: 0.215 | 0.2 | 53.9 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $1.39 EPS | TTM | $14.93 | -80.1% | $28.59 | -61.9% |
| $7.14 EPS | 2026 | $76.70 | 2.3% | $146.86 | 95.8% |
| $8.16 EPS | 2027 | $87.65 | 16.9% | $167.84 | 123.8% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 21.94% | 4.89% | 22.14% | 5.19% | 12.43% | 1.00% | 23.02% | 3.73% | 65.6% | 19.1% |
| 3 Years | 21.94% | 4.89% | 22.14% | 5.19% | 12.43% | 1.00% | 23.02% | 3.73% | 65.6% | 19.1% |
| 5 Years | 21.94% | 4.89% | 22.14% | 5.19% | 12.43% | 1.00% | 23.02% | 3.73% | 65.6% | 19.1% |
| 10 Years | 21.94% | 4.89% | 22.14% | 5.19% | 12.43% | 1.00% | 23.02% | 3.73% | 65.6% | 19.1% |